Janus Henderson Group
SMMT icon

Janus Henderson Group’s Summit Therapeutics SMMT Stock Holding History

Janus Henderson Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-76,590
Closed -$316K – 2577
2024
Q1 		$316K Buy
76,590
+15
+0% +$60 ﹤0.01% 2211
2023
Q4 		$200K Sell
76,575
-107
-0.1% -$220 ﹤0.01% 2437
2023
Q3 		$144K Buy
76,682
+28
+0% +$53 ﹤0.01% 2456
2023
Q2 		$193K Buy
+76,654
New +$140K ﹤0.01% 2454
2015
Q2 		– Sell
-139,166
Closed -$1.72M – 878
2015
Q1 		$1.72M Buy
+139,166
New +$1.58M 0.01% 546

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Janus Henderson Group's SMMT Position: Q2 2024 in Review

Janus Henderson Group sold out of Summit Therapeutics (SMMT) in Q2 2024, closing a stake of 76,590 shares — an estimated $316K sold.

Janus Henderson Group first reported a position in SMMT in Q1 2015 and held it in 5 quarters. The position peaked at $1.72M in Q1 2015. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

  • Janus Henderson Group reported no remaining Summit Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Janus Henderson Group sold 76,590 Summit Therapeutics shares in Q2 2024, an estimated $316K.
  • Janus Henderson Group first reported a position in Summit Therapeutics in Q1 2015 and held it in 5 quarters.
  • Janus Henderson Group's Summit Therapeutics position peaked at $1.72M in Q1 2015.
  • 123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on Janus Henderson Group's 13F filing for Q2 2024, filed 14 Aug 2024.